Clinical trial results:
Erlotinib treatment beyond progression in EGFR mutant or patients who have responded to EGFR TKI in stage IIIB/IV NSCLC

Summary

EudraCT number	2013-002049-13
Trial protocol	FI
Global end of trial date	31 December 2016

Results information

Result version number	v1 (current)
This version publication date	16 November 2021
First version publication date	16 November 2021
Summary attachment (see zip file)	Final report (ETAP final report signed.pdf)

Trial information

Trial identification

Sponsor protocol code	843

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	-
WHO universal trial number (UTN)	-

Notes:

Sponsors

Sponsor organisation name	Oulu Univeristy Hospital
Sponsor organisation address	Kajaanintie 50, Oulu, Finland, 90220
Public contact	Jussi Koivunen, Oulu University Hospital, 358 83153789, jussi.koivunen@ppshp.fi
Scientific contact	Jussi Koivunen, Oulu University Hospital, 358 83153789, jussi.koivunen@ppshp.fi

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	21 June 2017
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	31 December 2016
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

To study efficacy and safety of Erlotinib treatment beyound diasease progression in combination with chemotherapy compared to chemotherapy alone in stage IIIB/IV non-small cell lung cancer patients with EGFR activating mutations or who have responded EGFR TKIs-

Protection of trial subjects:

The trial was approved by PPSHP ethics committee (55/2013, EudraCT 2013-002049-13) and national competent authority (77/2013) and was carried out in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All patients provided written informed consent before any study-related procedures.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	01 August 2013
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	No

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Finland: 18
Worldwide total number of subjects	18
EEA total number of subjects	18

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37 wk	0
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	9
From 65 to 84 years	9
85 years and over	0

Subject disposition

Recruitment

Recruitment details:

18 out of planned 80 subject were recruited for the study.

Pre-assignment

Screening details:

E

Period 1

Period 1 title	Recruitement (overall period)
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes
Arm title	Chemotherapy

Arm description:

Chemoterapy treatment

Arm type	Active comparator
Investigational medicinal product name	Chemotherapy (multiple products)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for infusion
Routes of administration	Infusion

Dosage and administration details:

According to nationals guidelines

Arm title	Chemotherapy+Erlotinib

Arm description:

Chemotherapy+Erlotinib

Arm type	Experimental
Investigational medicinal product name	Chemotherapy (multiple products)
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Powder for infusion
Routes of administration	Infusion

Dosage and administration details:

According to national guidelines

Investigational medicinal product name	Erlotinib
Investigational medicinal product code	183320-12-9
Other name	
Pharmaceutical forms	Tablet
Routes of administration	Oral use

Dosage and administration details:

150mg x1 d5-18 Q3W for cycles 1-5 and thereafter daily 150mg x1

Number of subjects in period 1	Chemotherapy	Chemotherapy+Erlotinib
Started	9	9
Completed	9	9

Baseline characteristics

Reporting groups	
Reporting group title	Chemotherapy
Reporting group description: Chemoterapy treatment	
Reporting group title	Chemotherapy+Erlotinib
Reporting group description: Chemotherapy+Erlotinib	

Reporting group values	Chemotherapy	Chemotherapy+Erlotinib	Total
Number of subjects	9	9	18
Age categorical Units: Subjects			
In utero			0
Preterm newborn infants (gestational age < 37 wks)			0
Newborns (0-27 days)			0
Infants and toddlers (28 days-23 months)			0
Children (2-11 years)			0
Adolescents (12-17 years)			0
Adults (18-64 years)			0
From 65-84 years			0
85 years and over			0
Age continuous Units: months			
median	67	57	
full range (min-max)	49 to 73	37 to 76	-
Gender categorical Units: Subjects			
Female	7	4	11
Male	2	5	7
ECOG Units: Subjects			
ECOG 0-1	8	6	14
ECOG 2	1	3	4
EGFR mutation Units: Subjects			
ex19del	8	5	13
L858R	1	3	4
other	0	1	1
Previous EGFR TKI response Units: Subjects			
CR	0	0	0
PR	9	8	17
SD	0	1	1

End points

End points reporting groups	
Reporting group title	Chemotherapy
Reporting group description: Chemoterapy treatment	
Reporting group title	Chemotherapy+Erlotinib
Reporting group description: Chemotherapy+Erlotinib	

Primary: PFS (median)	
End point title	PFS (median)
End point description:	
End point type	Primary
End point timeframe: Progression-free survival (median)	

End point values	Chemotherapy	Chemotherapy +Erlotinib		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	9		
Units: months				
median (standard error)	14.71 (± 9.37)	18.27 (± 0.43)		

Statistical analyses

Statistical analysis title	Statistical analysis
Comparison groups	Chemotherapy v Chemotherapy+Erlotinib
Number of subjects included in analysis	18
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.05
Method	Logrank
Parameter estimate	Risk ratio (RR)
Confidence interval	
level	95 %
sides	1-sided
Variability estimate	Standard deviation

Secondary: OS (median)

End point title	OS (median)

End point description:

End point type	Secondary

End point timeframe:

Overall survival (median)

End point values	Chemotherapy	Chemotherapy +Erlotinib		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	9		
Units: months				
median (standard error)	8.28 (± 0.98)	9.66 (± 3.13)		

Statistical analyses

No statistical analyses for this end point

Secondary: ORR

End point title	ORR

End point description:

End point type	Secondary

End point timeframe:

ORR

End point values	Chemotherapy	Chemotherapy +Erlotinib		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	9	9		
Units: responses				
CR	0	0		
PR	2	1		
SD	3	5		
PD	3	3		

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information[1]	
Timeframe for reporting adverse events:	
From the date of IC to final visit (1-4motnhs after study treatment completion)	
Assessment type	Systematic

Dictionary used	
Dictionary name	MedDRA
Dictionary version	17

Reporting groups	
Reporting group title	Chemotherapy
Reporting group description: -	
Reporting group title	Chemotherapy+erlotinib
Reporting group description: -	

Notes:

[1] - There are no non-serious adverse events recorded for these results. It is expected that there will be at least one non-serious adverse event reported.
Justification: The study only collected serious adverse events

Serious adverse events	Chemotherapy	Chemotherapy+erlotinib	
Total subjects affected by serious adverse events			
subjects affected / exposed	6 / 9 (66.67%)	5 / 9 (55.56%)	
number of deaths (all causes)	1	0	
number of deaths resulting from adverse events	0	0	
Blood and lymphatic system disorders			
Pulmonary embolism			
subjects affected / exposed	1 / 9 (11.11%)	0 / 9 (0.00%)	
occurrences causally related to treatment / all	1 / 1	0 / 0	
deaths causally related to treatment / all	0 / 0	0 / 0	
General disorders and administration site conditions			
Fatigue			
subjects affected / exposed	1 / 9 (11.11%)	1 / 9 (11.11%)	
occurrences causally related to treatment / all	1 / 1	1 / 1	
deaths causally related to treatment / all	0 / 0	0 / 0	
Infections and infestations			
Neutropenic fever			
subjects affected / exposed	4 / 9 (44.44%)	2 / 9 (22.22%)	
occurrences causally related to treatment / all	4 / 4	2 / 2	
deaths causally related to treatment / all	0 / 0	0 / 0	

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Chemotherapy	Chemotherapy+erlotinib	
Total subjects affected by non-serious adverse events subjects affected / exposed	0 / 9 (0.00%)	0 / 9 (0.00%)	

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
04 January 2016	Increase the time of recruitement period to 31.12.2016

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported